Immunogenic Peptides Inducing CD8+ T Cell Immunity Against HSV
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Herpes Simplex Virus (HSV) infections are palliative and do not provide a cure, with many infected individuals being asymptomatic and unknowingly shedding the virus, leading to a need for effective inhibition and treatment methods.
Innovation Solution
Development of immunogenic peptides with specific amino acid sequences, such as NLLTTPKFT and RMLGDVMAV, formulated in compositions that induce CD8+ T cell-dependent protective immunity against HSV-1 and HSV-2 infections, using adjuvants like CpG1826 and lipid-tailed peptides, and incorporating epitopes from HSV-1 gB, gD, or other proteins.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If palliative treatments like acyclovir are used, then HSV infection symptoms are managed, but the infection cannot be cured and virus shedding continues
Solution Approach 1:
The patent applies preliminary action by administering immunogenic peptides containing HSV-specific epitopes before or during viral infection to proactively stimulate the immune system. This preventive immunization approach enables the host to develop CD8+ T cell responses in advance, allowing for more effective control of viral replication and shedding when infection occurs, rather than merely managing symptoms after infection is established
Solution Approach 2:
The patent uses immunogenic peptides as intermediaries to bridge the gap between the host immune system and the HSV virus. These peptides, containing specific epitopes from HSV proteins (such as gB, gD, and UL49.5), act as mediators that stimulate the immune system to recognize and respond to the virus, thereby enhancing the body's natural defense mechanisms without directly interacting with the virus itself
2Object-generated harmful factors
If asymptomatic individuals are not identified, then they unknowingly shed virus, but screening and identification methods are complex
Solution Approach 1:
The patent extracts specific immunogenic epitopes from complex HSV proteins to create simplified peptide compositions. By isolating and using only the critical epitopic regions (such as those from gB, gD, and UL49.5 proteins) that are recognized by protective T cell responses, the patent creates a streamlined diagnostic and therapeutic approach that avoids the complexity of analyzing entire viral proteins or using complex screening protocols
Solution Approach 2:
The patent applies universality by designing immunogenic peptides that can serve multiple functions: they can be used for both therapeutic vaccination to prevent infection and for diagnostic purposes to identify infected individuals. The peptides containing conserved epitopes from HSV-1 and HSV-2 can universally target both virus types, enabling a single intervention strategy to address diverse clinical scenarios including asymptomatic detection
Data Source
AI summary
Certain embodiments of the present invention provide immunogenic compositions that comprise one or more peptides having an amino acid sequence selected from the group consisting of NLLTTPKFT and RMLGDVMAV and methods for administering such compositions to a mammal and thereby inducing in the mammal a CD8+ T cell-dependent protective immunity against an HSV-1 infection, an HSV-2 infection, an HSV-1 condition, an HSV-2 condition, or combinations thereof.